CohBar — Q2 2021 Earnings Presentation
28 slides from CohBar's earnings presentation, Aug 10, 2021
Slide 1: Breakthrough Mitochondrial Science: Q2 Investor Presentation
Breakthrough Mitochondrial Science A Source for Novel Therapeutics Q2 Investor Presentation August 2021 NASDAQ: CWBR
Slide 2: Forward Looking Statements
Forward Looking Statements 2 This presentation contains forward - looking statements which are not historical facts within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements are based only on our current beliefs, expectations and assumptions regarding
Slide 3: Presentation Information
Presentation Information 3 Investor Update and Slide Presentation Date: August 10, 2021 Time: 5:00 p.m. (ET) 2:00 p.m. (PT) Conference Audio Dial - in U.S. and Canada: (877) 300 - 8521 Dial - in International: (412) 317 - 6026 Conference ID No.: 10159293 Slide Presentation Please visit the Zoom link
Slide 4: Today's Agenda
Today’s Agenda 4 • Overview • CB4211 Topline Data • Pipeline • Financials • Looking Ahead • Q&A
Slide 5: Overview
NASDAQ: CWBR Overview 5
Slide 6: CohBar Opportunity
6 CohBar Opportunity • Leader in developing mitochondria based therapeutics • Novel approach leveraging over a billion years of evolution • Recent clinical milestone • Positive CB4211 Phase 1a/1b topline data for lead candidate under development for NASH and obesity • Near - term milestones • IND fo
Slide 7: CB4211: Novel Mechanism of Action Relevant to NASH
SUBCUTANEOUS ADIPOSE TISSUE SYSTEMIC CIRCULATION PORTAL VEIN VISCERAL ADIPOSE TISSUE Splanchnic FFA Delivery HEPATOCYTE Targeting Free Fatty Acid Release from Fat Cells Inhibition/Regulation of Lipolysis • NALFD: excess free fatty acid released from abdominal fat cells by lipolysis - flows directly
Slide 8: Phase 1a/1b Study of CB4211: Topline Data
NASDAQ: CWBR A Phase 1a/1b Study of Safety, Tolerability, and Pharmacokinetics of CB4211 in Healthy Non - obese Subjects and Subjects with Nonalcoholic Fatty Liver Disease: Topline Data
Slide 9: CB4211 Phase 1a: Study Design and Subject Disposition
CB4211 Phase 1a: Study Design and Subject Disposition Phase 1a Study Design • Randomized, double - blind, placebo - controlled study • 6 cohorts of Single Ascending Dose (SAD) and 3 cohorts Multiple (7 - day) Ascending Dose (MAD) • Healthy adult volunteers (up to 8 per cohort) randomized (3:1) to CB
Slide 10: CB4211 Phase 1b: Study Design
CB4211 Phase 1b: Study Design CB4211 (25 mg QD SC) (n = 11) Placebo (n = 9) Baseline Week 4 Primary Endpoints: • Safety and tolerability Secondary Endpoint: • Pharmacokinetics Exploratory Endpoints: • Liver fat content (MRI - PDFF) • Body weight • Biomarkers of NASH and metabolic disease Screening •
Slide 11: CB4211 Phase 1b: Subject Disposition
CB4211 Phase 1b: Subject Disposition Phase 1b • 23 obese subjects with NAFLD were enrolled and randomized (1:1) to receive CB4211 or placebo • 3 subjects discontinued treatment before final assessment: 2 for COVID - 19, one withdrew consent • 20 subjects completed end of treatment PD assessments • F
Slide 12: Phase 1b Results: Changes in Key PD Biomarkers (Day 28)
Phase 1b Results: Changes in Key PD Biomarkers (Day 28) Biomarker CB4211 (25 mg) (n = 11) Placebo (n = 9) Difference from Placebo ALT (% reduction from baseline) - 21% 4% - 25%* Proportion of subjects with >17 U/L decrease in ALT (1) 27% 11% 16% AST (% reduction from baseline) - 28% - 11% - 17%* Glu
Slide 13: Phase 1b Results: CB4211 Significantly Reduced ALT and AST
Phase 1b Results: CB4211 Significantly Reduced ALT and AST Percent Change from Baseline in ALT CB4211 reduced ALT by 21% and AST by 28% at Week 4 0 1 2 3 4 -40% -30% -20% -10% 0% 10% Percent Change from Baseline in AST Weeks C h a n g e i n A S T * Placebo CB4211 Percent Change from Baseline in AST
Slide 14: Phase 1b Results: ALT Response Predictive of NASH Resolution
Phase 1b Results: ALT Response Predictive of NASH Resolution Proportion of Subjects with >17 U/L Decrease in ALT (1) Placebo CB4211 0% 10% 20% 30% Proportion >17 decALT 11% 27% (1) A decrease in ALT by 17 U/L or more is significantly associated with histologic response in NASH. (Loomba R et al. Gast
Slide 15: Phase 1b Results: Comparison to Historical ALT Data
Phase 1b Results: Comparison to Historical ALT Data for 4 - Week Studies (1) CB4211 reduced ALT as much or more than other NASH candidates Parameter CB4211 (CohBar) (25 mg) (SC injection) MET409 ( Metacrine ) (50 mg) (oral) DUR - 928 ( Durect ) (300 mg) (IV injection) CRV43 ( Hepion ) (225 mg) (oral
Slide 16: Phase 1b Results: CB4211 Reduced Fasting Glucose Levels
Phase 1b Results: CB4211 Reduced Fasting Glucose Levels Percent Change from Baseline in Glucose CB4211 reduced fasting glucose by 6% at Week 4 0 1 2 3 4 -10% -5% 0% 5% Percent Change from Baseline in Glucose Weeks C h a n g e i n G l u c o s e # Placebo CB4211 Data are mean +/ - SEM. *Statistically
Slide 17: Phase 1b Results: Change in Liver Fat Content (MRI-PDFF)
Phase 1b Results: Change from Baseline in Liver Fat Content (MRI - PDFF) Percent Absolute Reduction in LFC Placebo CB4211 -10% -8% -6% -4% -2% 0% -4.88% -5.03% Reduction in absolute LFC at Week 4 for CB4211 was comparable to other NASH candidates. However, liver fat content was also reduced in place
Slide 18: Phase 1a/1b Topline Safety Data: Positive Primary Outcome
Phase 1a/1b Topline Safety Data: Positive Primary Outcome Positive Results for Primary Outcome: Safety and Tolerability • CB4211 was well - tolerated and appeared safe with no serious adverse events • All adverse events were transient and generally mild to moderate • AEs occurring in >10% of subject
Slide 19: Phase 1b Topline Activity Data: Positive Exploratory Outcomes
Phase 1b Topline Activity Data: Positive Exploratory Outcomes Positive Results from Exploratory Trend Analysis at 4 Weeks • Robust and significant reductions in ALT, AST versus placebo • ALT reduction favorable vs other NASH candidates in 4 - week studies • ALT reduction predictive of potential bene
Slide 20: Pipeline
NASDAQ: CWBR Pipeline
Slide 21: NAFLD and NASH Disease Progression
Healthy Liver NAFLD Fat Accumulation (Steatosis) NASH Steatosis, Cellular Injury and Inflammation Fibrosis/ Cirrhosis Liver Failure Cancer (HCC) Transplant Death Nonalcoholic Steatohepatitis (NASH) Obesity/Type 2 Diabetes Metabolic Dysfunction Overnutrition Sedentary Lifestyle 21
Slide 22: Pipeline: MBT Programs
Pipeline MBT Programs Potential Indications Preclinical IND Enabling Activities Phase 1a Phase 1b Clinical CB4211 NASH Obesity Preclinical CB5138 - 3 IPF, Fibrotic Diseases Apelin Agonists COVID - 19 ARDS, ARDS CXCR4 Inhibitors Cancer, Other Diseases Immunotherapy Peptides Cancer Immunotherapy 22
Slide 23: Financials
NASDAQ: CWBR Financials
Slide 24: Summary Financials
Summary Financials Income Statement ($000s) 2Q 2021 2Q 2020 Research & Development $2,618 $1,545 General & Administrative 2,584 1,391 Net Loss (5,223) (4,103) Net Loss Per Share – Basic & Diluted (0.08) (0.09) Balance Sheet ($000s) 09/30/20 12/31/20 Cash & Investments $13,824 $21,015 Stockholders Eq
Slide 25: Looking Ahead
NASDAQ: CWBR Looking Ahead
Slide 26: Potential Milestones 2021-2022
Potential Milestones 2021 – 2022* 26 2H2021 • CB4211 • Initiate activities to support next CB4211 clinical study • Accelerate partnership discussions • Third clinical candidate: Select candidate and initiate IND enabling activities based on study results 2022 • CB5138 - 3 for IPF and other fibrotic
Slide 27: Q&A
NASDAQ: CWBR Q&A
Slide 28: Thank You
Thank You